TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$174 Million

Follow-on Offering

Bookrunner, June 2018

Rhythm Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.